p65BTK silencing or chemical inhibition affects the growth of CRC cells and overcomes the 5-FU resistance of p53-null CRC cells by abolishing a 5-FU-elicited TGFB1 protective response and triggering E2F-dependent apoptosis. The gene discussed is TP53; the disease is colorectal carcinoma.